Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bayer Benefits From Diversification, Despite Flat Pharma Growth in 2010

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm's ability to pursue smaller acquisitions or partnerships is improving because of a reduction in net debt.

You may also be interested in...



Diversification, Not Genzyme, Is The Theme Of Sanofi's Year-End Financial Report

Sanofi's sales declined by 1% in 2010 and net income increased by 2.6%, although €2 billion in sales were lost to generics during the year.

Novartis Splits Chair and CEO Positions, Names Joe Jimenez CEO

The news eclipses reports of a strong 2009, in which Novartis received 30 major regulatory approvals, and saw sales grow across major divisions

Bayer Purchase Of Schering AG Would Give Firm Focus On Specialty Pharma

$19. 5 bil. offer by Bayer will likely thwart hostile takeover of Schering by Merck KgaA.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS071927

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel